Roche's Tecentriq receives positive opinion from EU medicines agency
ZURICH (Reuters) - A European Medicines Agency (EMA) panel said on Friday it has recommended Roche's immunotherapy Tecentriq as a treatment for advanced bladder and lung cancer, setting the stage for European Commission approval this year.
No comments:
Post a Comment